News Sentiment

CAMP sentiment intelligence

CAMP4 THERAPEUTICS CORPORATION news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.71 Week of 17 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-14.3% over one week, -10.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -14.3% Price reacting lower
Trend fit Trend inactive -10.2% over four weeks
Fair value -12.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 26
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 7
GlobeNewswire 5
TradingKey 5
simplywall.st 3
Finviz 3
MT Newswires 3
Insider Monkey 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 13
Analyst action 8
Balance sheet 2
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
GlobeNewswire Direct company coverage

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics announced a non-qualified stock option grant to a new employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant involves 8,000 shares at an exercise price of $4.21 per share and will vest over a four-year period. This

Tone
Positive 61/100
Event
Market update
Published
18 Jul 2026 04:10
Source
GlobeNewswire
Stock Titan Direct company coverage

CAMP4 New Hire Gets Option on 8,000 Shares at $4.21

CAMP4 Therapeutics announced that its Board Compensation Committee granted a non-qualified stock option to a new employee to purchase 8,000 shares of common stock at an exercise price of $4.21 per share. This inducement grant, made under Nasdaq Listing Rule 5635(c)(4), has a 10-y

Tone
Positive 60/100
Event
Market update
Published
17 Jul 2026 19:41
Source
Stock Titan
Insider Monkey Direct company coverage

Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?

JPMorgan upgraded CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) to Overweight with a price target of $9, citing the potential undervaluation given the promise of CMP-002 for SYNGAP1-related disorder. The company also announced positive preclinical results for CMP-002, showing impr

Tone
Positive 75/100
Event
Earnings
Published
02 Jul 2026 16:06
Source
Insider Monkey
Insider Monkey Direct company coverage

8 Best Up and Coming Pharmaceutical Stocks to Buy Now

The article highlights CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) as a promising pharmaceutical stock, noting JPMorgan's upgrade to Overweight with a $9 price target due to potential of CMP-002 for SYNGAP1-related disorder. CAMP4's preclinical findings for CMP-002 showed signif

Tone
Positive 82/100
Event
Analyst action
Published
30 Jun 2026 18:04
Source
Insider Monkey
TradingKey Direct company coverage

CAMP4 Therapeutics Corp (CAMP) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of CAMP4 Therapeutics Corp (CAMP), noting its current valuation score of 6.02, which ranks 364 out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -1.79, indicating a significant deviation from it

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:09
Source
TradingKey
Finviz Direct company coverage

CAMP - CAMP4 Therapeutics Corp Revenue Breakdown

This article provides a detailed financial breakdown for CAMP4 Therapeutics Corp (CAMP), including its last close price, market capitalization, income, sales, key financial ratios, and performance metrics. It lists insider and institutional ownership, profitability margins, and s

Tone
Neutral 50/100
Event
Earnings
Published
23 Jun 2026 09:39
Source
Finviz
Stock Titan Direct company coverage

CAMP4 lures 3 new hires with 39,000 stock options

CAMP4 Therapeutics (Nasdaq:CAMP) has granted 39,000 non-qualified stock options to three new employees as an inducement to join the company. These options, with an exercise price of $3.96 per share, vest over four years with a 10-year term. This move aligns with Nasdaq Listing Ru

Tone
Positive 64/100
Event
Market update
Published
19 Jun 2026 20:09
Source
Stock Titan
GlobeNewswire Direct company coverage

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics, a clinical-stage biopharmaceutical company, announced stock option grants to three new employees as an inducement to employment. These grants, totaling 39,000 shares, are in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $3.96 per

Tone
Positive 62/100
Event
Market update
Published
19 Jun 2026 16:05
Source
GlobeNewswire
TradingKey Direct company coverage

CAMP4 Therapeutics Corp (CAMP) Institutional Confidence

CAMP4 Therapeutics Corp (CAMP) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. This score reflects an institutional shareholding proportion of 82.01%, a quarter-over-quarter increase of 237.71%. Steven

Tone
Positive 68/100
Event
Market update
Published
18 Jun 2026 16:40
Source
TradingKey
TradingKey Direct company coverage

CAMP4 Therapeutics Corp (CAMP) Financial Health: Profitability & Balance Sheet Analysis

TradingKey reports that CAMP4 Therapeutics Corp (CAMP) has a current financial score of 6.62, ranking 235 out of 388 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently saw a 50.82% year-over-year

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 06:12
Source
TradingKey
TradingKey Direct company coverage

CAMP4 Therapeutics Corp (CAMP) Earnings Forecast: Future EPS & Revenue Growth Estimates

CAMP4 Therapeutics Corp (CAMP) has an earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry. Analysts have an average price target of $7.50 for the stock, with a consensus "Buy" rating based on 7 analysts. The company's expected revenue fo

Tone
Positive 69/100
Event
Earnings
Published
18 Jun 2026 05:12
Source
TradingKey
TradingKey Direct company coverage

CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for CAMP4 Therapeutics Corp (CAMP). It indicates that the company has distributed $0.00 in dividends over the past five years and has no historical stock split data available. The page also presents current sto

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 11:09
Source
TradingKey
Investing.com Direct company coverage

JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential

JPMorgan has upgraded CAMP4 Therapeutics Corp (NASDAQ:CAMP) to Overweight and raised its price target to $9.00, citing the potential of its drug candidate CMP-002 for SYNGAP1-related disorder. The firm believes the stock is undervalued, anticipating CMP-002 will enter clinical tr

Tone
Positive 81/100
Event
Analyst action
Published
16 Jun 2026 05:39
Source
Investing.com
Stock Titan Direct company coverage

Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike

Camp4 Therapeutics director Stewart Murray was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. These options will vest fully on the earlier of the first anniversary of the grant date or the company's next annual meeting of stockho

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 00:13
Source
Stock Titan
Stock Titan Direct company coverage

Camp4 Therapeutics director granted 28K options | CAMP Insider Trading

Camp4 Therapeutics director and 10% owner Amir Nashat was granted 28,000 stock options with an exercise price of $4.34 per share; no cash was paid at the time of the grant. The options vest fully on the earlier of the first anniversary of the grant date or the company's next annu

Tone
Neutral 50/100
Event
Balance sheet
Published
13 Jun 2026 02:09
Source
Stock Titan
Stock Titan Direct company coverage

Camp4 Therapeutics (CAMP) director awarded 28,000 stock options

Camp4 Therapeutics (CAMP) director Douglas E. Williams was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options will fully vest on the earlier of the first anniversary of the grant date or the company's next annual meeting,

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Camp4 Therapeutics (CAMP) grants director 28,000 stock options

Camp4 Therapeutics Corp. director Richard A. Young was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the company's next annual meeting, continge

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Camp4 Therapeutics director granted 28,000 options | CAMP Insider Trading

Camp4 Therapeutics director Steven H. Holtzman was granted 28,000 stock options with an exercise price of $4.34 per share, expiring on June 9, 2036. The options will vest on the earlier of the first anniversary of the grant date or the company's next annual shareholder meeting, p

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:09
Source
Stock Titan
Investing.com Direct company coverage

Chardan initiates CAMP4 Therapeutics stock with buy rating

Chardan has initiated coverage on CAMP4 Therapeutics with a buy rating and a price target of $6.50, citing significant upside potential from its current trading price of $4.01. The biotechnology company, specializing in antisense oligonucleotides for neurodevelopmental disorders

Tone
Positive 86/100
Event
Analyst action
Published
11 Jun 2026 13:09
Source
Investing.com
Investing.com Australia Direct company coverage

Chardan initiates CAMP4 Therapeutics stock with buy rating By Investing.com

Chardan has initiated coverage on CAMP4 Therapeutics (NASDAQ:CAMP) with a buy rating and a price target of $6.50, citing significant upside potential from its current trading price of $4.01. The clinical-stage biotechnology company, supported by research from MIT's Whitehead Inst

Tone
Positive 72/100
Event
Analyst action
Published
11 Jun 2026 02:40
Source
Investing.com Australia
GuruFocus Direct company coverage

CAMP Initiated Coverage by Chardan Capital -- Rating Set to Buy

Chardan Capital has initiated coverage on Camp4 Therapeutics (CAMP) with a "Buy" rating and a price target of $6.50, citing the company's pioneering work in RNA-based therapeutics for genetic diseases. Despite this positive outlook, Camp4 Therapeutics holds a low GF Score™ of 8/1

Tone
Positive 73/100
Event
Analyst action
Published
10 Jun 2026 15:09
Source
GuruFocus
Market source Direct company coverage

Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation

Camp4 Therapeutics (NASDAQ:CAMP) has seen its stock rise 114% in the last year despite not yet making a profit. The company has a cash runway of 3.8 years, with $99 million in cash and a cash burn of $26 million in the past year. Analysts are optimistic about its revenue growth o

Tone
Positive 69/100
Event
Balance sheet
Published
06 Jun 2026 12:39
Source
Market source
Finviz Direct company coverage

CAMP - CAMP4 Therapeutics Corp Options

This page provides a detailed financial overview of CAMP4 Therapeutics Corp (CAMP), including its stock performance, key financial metrics, and company statistics. It covers areas such as market capitalization, income, sales, insider and institutional ownership, and various perfo

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 22:39
Source
Finviz